HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. I. Description of the algorithm

Human Immunology

Volumn 63, Issue 5, 2002, Pages 339-352

  Duquesnoy, René J ^a,b  

^a Department of Pathology   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Highly sensitized patients; Histocompatibility; HLAMatchmaker triplet; PRA

Indexed keywords

ALLOANTIBODY; AMINO ACID; EPITOPE; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN;

ALGORITHM; ALLOIMMUNIZATION; AMINO ACID SEQUENCE; ARTICLE; BLOOD DONOR; CODON; COMPUTER PROGRAM; CROSS REACTION; DNA POLYMORPHISM; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; SENSITIZATION; SERUM; THROMBOCYTE TRANSFUSION; TRANSPLANTATION;

ALGORITHMS; AMINO ACIDS; ANTIBODY SPECIFICITY; COMPUTATIONAL BIOLOGY; GENES, MHC CLASS I; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; POLYMORPHISM, GENETIC; QUALITY CONTROL;

EID: 0036092367     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(02)00382-8     Document Type: Article

References (85)

1. Prediction of crossmatch outcome in highly sensitized dialysis patients based on the identification of serum HLA antibodies
2. The definition of HLA specificities by cytotoxicity
3. Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity
4. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: Identification of low levels of pre-formed antibodies in accelerated allograft rejection
5. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test
6. HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure
7. Enzyme-linked immunoassay for anti-HLA antibodies - An alternative to panel studies by lymphocytotoxicity
8. Detection of panel-reactive anti-HLA class I antibodies by enzyme-linked immunosorbent assay or lymphocytotoxicity: Results of a blinded, controlled multicenter study
9. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection
10. Evaluation of HLA antibodies with the PRA-STAT test. An ELISA test using soluble HLA class I molecules
11. Antibodies to cross-reactive HLA antigens. Evaluation by cytotoxicity, flow cytometry, and inhibition of monoclonal antibody binding
12. Detection of alloantibodies by flow cytometry: Relevance to clinical transplantation
13. Detection of HLA class I- and class II-specific antibodies by flow cytometry and PRA-STAT screening in renal transplant recipients
14. The occurrence of cross-reactive "public" antibodies in the sera of highly sensitized dialysis patients
15. New approaches to donor crossmatching and successful transplantation of highly sensitized patients
16. The effect of HLA-A, -B matching on cadaver renal allograft rejection comparing public and private specificities
17. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation
18. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients
19. Epitope specificity of HLA class I alloantibodies: II. Stability of cross-reactive group antibody patterns over extended time periods
20. Identification of antibodies toward private and public class I HLA epitopes in sensitized patients
21. CREG matching for first cadaveric kidney transplants (TNX) performed by SEOPF centers between October 1987 and September 1995
22. The predictive value of epitope analysis in highly sensitized patients awaiting renal transplantation
23. Determination of HLA-A,B residue mismatch acceptability for kidneys transplanted into highly sensitized patients: A report of a collaborative study conducted during the 12th International Histocompatibility Workshop
24. Public epitopes and the antigenic structure of the HLA molecules
25. Adsorption of cytotoxic anti-HLA antibodies with HLA class I immunosorbant beads
26. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation
27. A microabsorption assay to determine acceptable HLA-A and B mismatches for highly immunized patients
28. Hyperimmunized patients do not need to wait for an HLA identical donor
29. Taboo HLA mismatches in cadaveric renal transplantation: Definition, analysis, and possible implications
30. Acceptable HLA mismatches for highly immunized patients
31. Epitope map of the HLA-B7 CREG using affinity-purified human alloantibody probes
32. Topographic map of the HLA-A2 CREG epitopes using human alloantibody probes
33. Serological mapping of HLA-epitopes with monoclonal antibodies and its interpretation by sequenced HLA-molecules
34. Serologic cross-reactivities poorly reflect allelic relationships in the HLA-B12 and HLA-B21 groups. Dominant epitopes of the alpha 2 helix
35. HLA-Bw22: A family of molecules with identity to HLA-B7 in the alpha 1-helix
36. HLA-B15: A widespread and diverse family of HLA-B alleles
37. HLA-B67: A member of the HLA-B16 family that expresses the ME1 epitope
38. Structural diversity in the HLA-A10 family of alleles: Correlations with serology
39. HLA-B*0702 antibody epitopes are affected indirectly by distant antigen residues
40. Mutagenesis around residue 176 on HLA-B*0702 characterizes multiple distinct epitopes for anti-HLA antibodies
41. Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw 4 and Bw6
42. The origins of HLA-A,B,C polymorphism
43. The HLA-B73 antigen has a most unusual structure that defines a second lineage of HLA-B alleles
44. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule
45. Structure of the human class I histocompatibility antigen, HLA-A2
46. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Angstrom resolution
47. The three-dimensional structure of HLA-B27 at 2: 1 A resolution suggests a general mechanism for tight peptide binding to MHC
48. Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705
49. Recognition of CD8 on cytotoxic T-lymphocytes is ablated by several substitutions in the class I alpha domains: CD8 and T-cell receptor recognize the same class I molecule
50. Polymorphisms in the alpha-3 domain of HLA-A molecules affects binding to CD8
51. Alloantibodies to an antigenic determinant shared by HLA-A2 and B17
52. HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients
53. Antigenicity of HLA-A2 and HLA-B7: Loss and gain of serologic determinants induced by site-specific mutagenesis at residues 62 to 80
54. Supertypic HLA-Bw4 antigen detected by a new monoclonal antibody
55. Quantitative estimation of HLA-A and HLA-B antigens carrying the Bw4 supertypic specificity in human peripheral blood lymphocytes
56. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes
57. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA
58. Low immunogenicity of the third HL-A series
59. Role of HLA-C matching in histocompatibilty platelet transfusion therapy of alloimmunized thrombocytopenic patients
60. Distinctive polymorphism at the HLA-C locus: Implications for the expression of HLA-C
61. Predictive values for a negative crossmatch of sensitized renal recipients: Triplet amino acid matching vs CREG matching
62. The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients
63. Attempts to locate residues in complementarity-determining regions of antibody-combining sites that make contact with antigen
64. The structural basis of antibody complementarity
65. The chemistry and mechanism of antibody binding to protein antigens
66. Structure of antibody-antigen complexes: Implications for immune recognition
67. Epitopes on protein antigens: Misconception and realities
68. Molecular dissection of protein antigens
69. A priori delination of a peptide which mimics a discontinuous antigenic determinant
70. Antigenic cross-reactivity potential of synthetic peptides immobilzed on polystyrene rods
71. Epitopes of an influenza viral peptide recognized by antibody at a single amino acid resolution
72. HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes
73. Antigen Society No. 15 Report (Bw4 and Bw6)
74. Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix
75. Benefits of HLA-CREG matching for sensitized recipients as illustrated in kidney regrafts
76. Matching for private and public HLA epitopes reduces acute rejection and improves two-year renal allograft function
77. CREG matching for first kidney transplants performed by Seopf Centers between October 1987 and September 1995 - An analysis of outcome and prospective benefit
78. Evaluation of the permissible mismatch concept
79. HLA and cross-reactive antigen group matching for cadaver kidney allocation
80. Cross-reactive group matching does not lead to a better allocation and survival of donor kidneys
81. Transplantation of highly sensitized patients on the basis of acceptable HLA-A and B mismatches
82. Anti-HLA antibodies after solid organ transplantation